Best of the Blog: IN VIVO, May/June 2009

Our favorite blog posts related to stories not covered elsewhere in this month's IN VIVO.

"Best of the Blog" is a monthly column highlighting the best of our free online content at www.windhover.com/blog. In May and June, Windhover’s editorial staff posted nearly 100 articles to the site, covering biopharma R&D, business development, regulatory and commercial news. Highlights included our blogging on location at the BIO meeting in Atlanta and our ongoing coverage of health care reform issues like comparative effectiveness research (not to mention the ongoing web-dominance of Deals of the Week!). Here are a few of our favorite blog posts and excerpts for stories not covered elsewhere in this month’s IN VIVO.

(May 11.) The recently and some-say miraculously approved iloperidone (Fanapt) from Vanda Pharmaceuticals Inc. is certainly a rare bird....

Welcome to In Vivo

Create an account to read this article

More from Business Strategy

Podcast: “They Are Able To Keep Their Body”: Medipost On Its Stem Cell Therapy Vision

 

In Vivo spoke with Edward Ahn, CEO of Medipost, a Korean company that has developed stem cell therapies from cord blood, on how they are working across regulatory markets to provide a novel treatment for degenerative diseases.

Can Italy Shake Off Its Reputation And Become A Premier Hub For Biotech?

 
• By 

Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.

Rising Leaders 2025: Abbas Kazimi’s Vision For Nimbus Therapeutics

 
• By 

Rising Leader Abbas Kazimi's leadership at Nimbus Therapeutics combines immigrant resilience, patient-first partnerships, contrarian strategic bets and a deeply personal mission driving breakthrough drug discovery innovation.

AI In Biologics Discovery: The Expensive Bet On Unproven Promise

 
• By 

Despite limited evidence of commercial impact, pharmaceutical companies are making massive strategic investments in AI biologics platforms. The question isn't whether the technology shows promise; it's whether that promise can translate to measurable business results.

More from In Vivo

Deals In Depth: June 2025

 
• By 

Five $1bn+ alliances were penned in June, and four exceeded $2bn.

Global Pharma Interest In Korea Undeterred Despite Political Roller Coaster

 
• By 

Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.

Podcast: Oxolife’s Agnés Arbat, Winner Of The European Prize For Women Innovators

 
• By 

Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.